Table 2.

Prevalence of Injection Site Pain in Patients with Type 1 Diabetes during Long-Term Treatment with BIOD-090.

Interval	Continuing BIOD-090 from prior study n = 100	Starting BIOD-090 in extension study n = 123	Overall n = 223
Week 0 to 4	5.2% (5/97)	22.8% (28/123)	15.0% (33/220)
Week 4 to 9	N/A (0/0)	13.4% (15/112)	13.4% (15/112)
Week 9 to 18	3.2% (3/95)	5.7% (6/106)	4.5% (9/201)
Week 18 to 31	3.2% (3/93)	4.2% (4/95)	3.7% (7/188)
Week 31 to 45	1.2% (1/84)	1.1% (1/87)	1.2% (2/171)
Week 45 to 58	2.5% (2/81)	6.1% (5/82)	4.3% 7/163)
Week 58 to 72	1.5% (1/65)	1.4% (1/69)	1.5% (2/134)